3 ASX healthcare stocks soaring on positive company updates

These companies have exciting news for investors today.

| More on:
Three health professionals at a hospital smile for the camera.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX healthcare stocks are in the green on Friday, with the S&P/ASX 200 Health Care Index (ASX: XHJ) 0.41% higher while the benchmark S&P/ASX 200 Index (ASX: XJO) is up 0.32%.

Here are three of the best-performing ASX healthcare shares and why they are rising on Friday.

3 ASX healthcare shares zooming higher on positive news

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is up 7.9% at 61 cents per share at the time of writing.

The respiratory imaging technology company's shares are lifting on news of a commercial agreement with Qscan Radiology Clinics (QScan).

The contract follows a successful pilot of 4DMedical's products with Qscan, which is a leading provider of diagnostic imaging services in Queensland.

Under the deal, Qscan will offer 4DMedical's respiratory imaging solutions at select practices in Brisbane.

This is the first Australian contract for 4DMedical that incorporates products from both its pulmonary function and pulmonary structure suites, including CT LVAS.

4DMedical CEO and founder Andreas Fouras said:

Momentum continues to build with the commercialisation of our technology across the US and Australia.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

The Paradigm Biopharmaceuticals share price is 5.7% higher at 47 cents per share.

Paradigm is an ASX biotech that is focused on repurposing Pentosan Polysulfate Sodium (PPS) for the treatment of knee osteoarthritis.

The company announced today that it has received a $6,300,438 research and development (R&D) tax incentive refund from the Australian Government for the 2024 financial year.

This raises the company's current cash balance to approximately $31 million.

Paradigm managing director Paul Rennie commented:

With our cash position further boosted with this incentive refund, we are well-positioned to progress our Phase 3 clinical trial activities and subject recruitment in Australia.

The R&D tax incentive program is designed to encourage innovation through R&D activities in
Australia. Eligible companies can receive refundable cash offsets of 43.5% for qualifying R&D costs.

Somnomed Ltd (ASX: SOM)

The Somnomed share price is 6.7% higher at 64 cents per share.

Somnomed designs and manufactures oral treatments for sleep-related breathing disorders and obstructive sleep apnea.

The company released its December quarter activities report and FY25 guidance update today.

Somnomed reported 2Q FY25 revenue of $28.5 million, up 19.8% on the prior corresponding period (pcp).

Net cash inflow from operating activities was positive at $1.5 million.

The cash balance at the end of the quarter was $18.5 million, with a $1 million unsecured loan facility in Europe fully drawn.

For FY25, the company now expects revenue of approximately $105 million and earnings before interest, taxes, depreciation, and amortisation (EBITDA) of between $7 million and $9 million.

It expects capex costs of between $3 million to $4 million.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »